Global RNAi Technologies Market Professional Survey Report 2019

2 Global RNAi Technologies Quarterly Market Size Analysis

• 2.1 RNAi Technologies Business Impact Assessment - COVID-19
  • 2.1.1 Global RNAi Technologies Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global RNAi Technologies Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global RNAi Technologies Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, RNAi Technologies Headquarters and Area Served
• 3.3 Date of Key Players Enter into RNAi Technologies Market
• 3.4 Key Players RNAi Technologies Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on RNAi Technologies Segments, By Type

• 4.1 Introduction
  • 1.4.1 Oncology
  • 1.4.2 Ocular disorders
  • 1.4.3 Respiratory disorders
  • 1.4.4 Liver diseases
  • 1.4.5 Other
• 4.2 By Type, Global RNAi Technologies Market Size, 2019-2021

5 Impact of Covid-19 on RNAi Technologies Segments, By Application

• 5.1 Overview
  • 5.5.1 Research
  • 5.5.2 Therapeutics
• 5.2 By Application, Global RNAi Technologies Market Size, 2019-2021
  • 5.2.1 By Application, Global RNAi Technologies Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Alnylam Pharmaceuticals
  • 7.1.1 Alnylam Pharmaceuticals Business Overview
  • 7.1.2 Alnylam Pharmaceuticals RNAi Technologies Quarterly Revenue, 2020
  • 7.1.3 Alnylam Pharmaceuticals RNAi Technologies Product Introduction
  • 7.1.4 Alnylam Pharmaceuticals Response to COVID-19 and Related Developments
• 7.2 Benitec Biopharma Ltd
  • 7.2.1 Benitec Biopharma Ltd Business Overview
  • 7.2.2 Benitec Biopharma Ltd RNAi Technologies Quarterly Revenue, 2020
  • 7.2.3 Benitec Biopharma Ltd RNAi Technologies Product Introduction
  • 7.2.4 Benitec Biopharma Ltd Response to COVID-19 and Related Developments
• 7.3 Filmtec Corporation
  • 7.3.1 Filmtec Corporation Business Overview
  • 7.3.2 Filmtec Corporation RNAi Technologies Quarterly Revenue, 2020
  • 7.3.3 Filmtec Corporation RNAi Technologies Product Introduction
  • 7.3.4 Filmtec Corporation Response to COVID-19 and Related Developments
• 7.4 Ionis Pharmaceuticals
  • 7.4.1 Ionis Pharmaceuticals Business Overview
  • 7.4.2 Ionis Pharmaceuticals RNAi Technologies Quarterly Revenue, 2020
  • 7.4.3 Ionis Pharmaceuticals RNAi Technologies Product Introduction
  • 7.4.4 Ionis Pharmaceuticals Response to COVID-19 and Related Developments
• 7.5 Quark Pharmaceuticals Inc.
  • 7.5.1 Quark Pharmaceuticals Inc. Business Overview
  • 7.5.2 Quark Pharmaceuticals Inc. RNAi Technologies Quarterly Revenue, 2020
  • 7.5.3 Quark Pharmaceuticals Inc. RNAi Technologies Product Introduction
  • 7.5.4 Quark Pharmaceuticals Inc. Response to COVID-19 and Related Developments
• 7.6 RXI Pharmaceuticals
  • 7.6.1 RXI Pharmaceuticals Business Overview
  • 7.6.2 RXI Pharmaceuticals RNAi Technologies Quarterly Revenue, 2020
  • 7.6.3 RXI Pharmaceuticals RNAi Technologies Product Introduction
  • 7.6.4 RXI Pharmaceuticals Response to COVID-19 and Related Developments
• 7.7 Qiagen
  • 7.7.1 Qiagen Business Overview
  • 7.7.2 Qiagen RNAi Technologies Quarterly Revenue, 2020
  • 7.7.3 Qiagen RNAi Technologies Product Introduction
  • 7.7.4 Qiagen Response to COVID-19 and Related Developments
• 7.8 Invitrogen
  • 7.8.1 Invitrogen Business Overview
  • 7.8.2 Invitrogen RNAi Technologies Quarterly Revenue, 2020
  • 7.8.3 Invitrogen RNAi Technologies Product Introduction
  • 7.8.4 Invitrogen Response to COVID-19 and Related Developments
• 7.9 Ambion
  • 7.9.1 Ambion Business Overview
  • 7.9.2 Ambion RNAi Technologies Quarterly Revenue, 2020
  • 7.9.3 Ambion RNAi Technologies Product Introduction
  • 7.9.4 Ambion Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US